Scancell Holdings Share News (SCLP)

Scancell Holdings Information

Buy SCLP Shares
Add SCLP to Watchlist
Add SCLP to Alert

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 10.10

Bid: 9.70

Ask: 10.50

Change: 0.00 (0.00%)

Spread: 0.80 (8.247%)

Open: 10.10

High: 10.10

Low: 10.10

Prev. Close: 10.10

Last checked at -

Scancell doses first patient in melanoma-focused trials

Tue, 26th Mar 2024 14:00

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.

The Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases said the patient also received a combination of ipilimumab and nivolumab.

The therapeutic is a modified version of the human leukocyte antigen dependent SCIB1 used to treat melanoma patients. Scancell believes the latest version will treat a broader range of patients beyond the 40% treated with SCIB1.

Data from the latest cohort is expected in the final quarter of 2024 and, if effective, the treatment may give the company a foothold in a USD1.5 billion market.

Shares in Scancell were up 4.8% to 10.75 pence on Tuesday afternoon in London.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

More News

4 Apr 2016 09:31

Scancell Raises Further Funding Through Open Offer (ALLISS)

1 Apr 2016 11:27

CORRECT: Scancell Raises Funds In Placing, Open Offer (ALLISS)

1 Apr 2016 09:06

Scancell Raises Total Of GBP6.1 Million In Placing, Open Offer (ALLISS)

11 Mar 2016 08:51

Scancell skips higher on Swedish research collaboration

(ShareCast News) - Immuno-oncology specialist Scancell has impressed investors with a new research partnership with Sweden's Karolinska Institutet into the role of citrullinated proteins in the treatment of cancer. Both parties have uncovered important roles that citrullinated proteins can play in h

11 Mar 2016 08:01